Long-Term Anticoagulation After Stroke
Most patients with ischemic stroke who have atrial fibrillation are managed with long-term oral anticoagulation rather than stopping after a short fixed course.[1] If the stroke was non-cardioembolic and atrial fibrillation is not present, long-term anticoagulation with apixaban is typically not indicated, and antiplatelet therapy is preferred.[1]
Medication Duration Framework
Duration of apixaban after stroke is determined by the stroke mechanism and the indication for anticoagulation rather than by the stroke event date alone.[1]
Indications Supporting Indefinite Continuation
- Atrial fibrillation after ischemic stroke
- Long-term oral anticoagulation is indicated as secondary prevention in patients with acute stroke without contraindications in whom atrial fibrillation is the driver of cardioembolism.[2]
- Most ischemic stroke patients with atrial fibrillation should be anticoagulated.[1]
Indications Against Routine Continuation
- Non-cardioembolic ischemic stroke
- Patients with non-cardioembolic ischemic stroke should be treated with antiplatelet medication rather than anticoagulation.[1]
Reassessment Triggers
Anticoagulation continuation should be reassessed when contraindications develop or when the original indication no longer applies.[1]
Common Clinical Discontinuation Scenarios
- High bleeding risk or clinically significant bleeding
- Oral anticoagulation is not continued if contraindications or unacceptable bleeding risk outweigh stroke prevention benefit.[1]
Targets of Therapy
The goal of continuing apixaban for an atrial fibrillation–related stroke is prevention of recurrent stroke and systemic embolism through sustained anticoagulation.[1][2]
Practical Medication-Stop Planning Considerations
Stopping apixaban should be coordinated with the treating clinician because management then typically shifts to an alternative secondary prevention strategy depending on the stroke mechanism.[1]